Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00332566 | Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib | PHASE3 | COMPLETED | 148 | — | — | Jun 1, 2006 | Oct 1, 2006 | Sep 28, 2016 | 2 | Argentina, Nicaragua |
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DTPw-HBV/Hib Kft vaccine GSK323527A | BIOLOGICAL | Intramuscular injection, 1 dose |
| Tritanrix™-HepB/Hiberix™ | BIOLOGICAL | Intramuscular injection, 1 dose |
Inclusion Criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female toddler, 18 to 24 months of age at the time of booster vaccination, who completed the three-dose pr...